Skip to Content
Merck

SML1394

Olmesartan

≥98% (HPLC), Angiotensin II Type I receptor blocker, powder

Synonym(s):

4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid, Olmesartan acid

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C24H26N6O3
CAS Number:
144689-24-7
Molecular Weight:
446.50
UNSPSC Code:
12352200
PubChem Substance ID:
329825842
NACRES:
NA.77
MDL number:
MFCD09749896
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Olmesartan, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

SMILES string

OC(C)(C)C1=C(C(O)=O)N(CC2=CC=C(C3=C(C4=NNN=N4)C=CC=C3)C=C2)C(CCC)=N1

InChI

1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)

InChI key

VTRAEEWXHOVJFV-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

Related Categories

Application

Olmesartan has been used as an angiotensin II receptor 1 (AT1) receptor inhibitor to study the effect of angiotensin II type 1 receptor interactions in the regulation of renal afferent arterioles in angiotensin II-dependent hypertension.

Biochem/physiol Actions

Olmesartan is an Angiotensin II Type I receptor blocker.
Olmesartan is an Angiotensin II Type I receptor blocker. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil.
Olmesartan possesses anti-inflammatory and anti-oxidative stress properties. It protects neuronal cells against oligomerized amyloid β (Aβ)-induced cellular senescence.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000390400
0000381193
0000381193
0000390400
0000249586

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jian Wang et al.
ACS chemical neuroscience, 12(7), 1162-1169 (2021-03-13)
Alzheimer's disease (AD) is a neurodegenerative disease with high morbidity. The deposition of oligomerized amyloid β (Aβ) is the pathological feature of AD. The Aβ-caused neuronal oxidative stress and cellular senescence play an important role in the development and progression
Naif O Al-Harbi et al.
Inflammopharmacology, 27(4), 817-827 (2019-01-03)
Carfilzomib (CFZ), a proteasome inhibitor approved by the FDA to treat multiple myeloma, may cause nephrotoxicity. Rutin is a bioflavonoid with antioxidant properties. We aimed to examine whether rutin protects the kidney from CFZ-induced nephrotoxicity. This study aimed to demonstrate
Yi Zhou et al.
Cells, tissues, organs, 204(1), 25-37 (2017-05-10)
Animal studies have reported on the benefits of ARB on bone mass. However, the underlying mechanism for angiotensin II (AngII)/AngII receptor blockade (ARB) in regulating bone mass remains elusive. Since high levels of plasma and urine cAMP are observed in
Haiyi Chen et al.
ACS chemical neuroscience, 10(1), 677-689 (2018-09-29)
The number of solved G-protein-coupled receptor (GPCR) crystal structures has expanded rapidly, but most GPCR structures remain unsolved. Therefore, computational techniques, such as homology modeling, have been widely used to produce the theoretical structures of various GPCRs for structure-based drug
Valeria Avataneo et al.
British journal of clinical pharmacology, 84(11), 2535-2543 (2018-07-05)
Arterial hypertension is an important cardiovascular risk factor. A substantial proportion of patients show resistance to antihypertensive treatment but poor adherence to medication regimens is also a significant cause of treatment failure. In this context, therapeutic drug monitoring (TDM) could
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service